Mark HIBBERD,Vijaykumar Reddy RAJASEKHAR,Brendan Mark JOHNSON,Lynn SEELY,Paul N. MUDD, JR.,Susan WOLLOWITZ,Masataka TANIMOTO,Mayukh Vasant SUKHATME
申请号：
MX2019003726
公开号：
MX2019003726A
申请日:
2017.09.29
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-met hoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyr imidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding； and methods of contraception and treating infertility.Metodos para tratar fibroides uterinos, endometriosis, adenomiosis, o sangrado menstrual abundante en un sujeto, que incluyen administrar al sujeto entre 10 mg y 60 mg por dia de N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metoxi- 3-piridazinil)-2,4-dioxo- 1,2,3,4-tetrahidrotieno[2,3-d]pirimidin- 6-il)fenil)-N'-metoxiurea, y entre 0,01 mg y 5 mg por dia de un medicamento de reemplazo hormonal； la presente divulgacion tiene metodos para reducir el sangrado menstrual en un sujeto, reducir la perdida de densidad mineral osea en un sujeto causada por la administracion de un antagonista de GnRH al sujeto, suprimir las hormonas sexuales en un sujeto, reducir los sintomas vasomotores o sofocones de calor en un sujeto, y reducir los sintomas de disminucion de la libido en un sujeto que tiene fibroides uterinos, endometriosis,
